{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T13:55:18Z","timestamp":1736776518104,"version":"3.33.0"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJHP"],"abstract":"<jats:p>Background: Despite data derived from observational studies, optimal anticoagulation strategies have yet to be established for patients with nonvalvular atrial fibrillation and obesity.\nObjective: To describe direct oral anticoagulant (DOAC) regimens prescribed for adult patients with nonvalvular atrial fibrillation who weighed more than 120 kg.\nMethods: This single-centre, retrospective cohort study, conducted in the Saskatchewan Health Authority \u2013 Regina Area, involved adult patients with body weight greater than 120 kg who had an indication for oral anticoagulation to treat nonvalvular atrial fibrillation and were discharged by a cardiologist between June 2019 and July 2021.\nResults: A total of 62 patients were included (median weight 135 kg). At discharge, DOACs were prescribed for 57 (92%) of the patients and warfarin for 5 (8%). In numeric terms, patients receiving warfarin were at higher risk of thromboembolism or thrombosis; however, the small sample size limited the ability to draw conclusions.\nConclusions: Practice patterns in the Saskatchewan Health Authority \u2013 Regina Area indicated substantial use of DOACs for patients with body weight greater than 120 kg; however, for those with the highest weights, warfarin was still in use.\nKeywords: atrial fibrillation, obesity, direct oral anticoagulants, anticoagulation, pharmacist interventions, pharmacist\nR\u00c9SUM\u00c9\nContexte : Malgr\u00e9 les donn\u00e9es d\u00e9riv\u00e9es d\u2019\u00e9tudes observationnelles, les strat\u00e9gies d\u2019anticoagulation optimales n\u2019ont pas \u00e9t\u00e9 consolid\u00e9es pour les patients atteints de fibrillation auriculaire non valvulaire et d\u2019ob\u00e9sit\u00e9.\nObjectif : D\u00e9crire les sch\u00e9mas th\u00e9rapeutiques d\u2019anticoagulants oraux (ACO) prescrits aux patients adultes atteints de fibrillation auriculaire non valvulaire et qui pesaient plus de 120 kg.\nM\u00e9thodes : Cette \u00e9tude de cohorte r\u00e9trospective monocentrique men\u00e9e dans l\u2019office de la sant\u00e9 de la Saskatchewan \u00e0 Regina a port\u00e9 sur des patients adultes pesant plus de 120 kg qui avaient une indication de traitement anticoagulant oral pour traiter la fibrillation auriculaire non valvulaire et qui ont \u00e9t\u00e9 renvoy\u00e9s par un cardiologue entre juin 2019 et juillet 2021.\nR\u00e9sultats : Au total, 62 patients ont \u00e9t\u00e9 inclus (poids m\u00e9dian, 135 kg). Au cong\u00e9, des ACO ont \u00e9t\u00e9 prescrits \u00e0 57 (92 %) des patients et de la warfarine \u00e0 5 (8 %) d\u2019entre eux. En termes num\u00e9riques, les patients trait\u00e9s par warfarine pr\u00e9sentaient un risque plus \u00e9lev\u00e9 de thromboembolie ou de thrombose; cependant, la petite taille de l\u2019\u00e9chantillon a limit\u00e9 la capacit\u00e9 de tirer des conclusions.\nConclusions : Les mod\u00e8les de pratique de l\u2019office de la sant\u00e9 de la Saskatchewan \u00e0 Regina indiquaient une utilisation importante des ACO pour les patients dont le poids corporel \u00e9tait sup\u00e9rieur \u00e0 120 kg; cependant, pour les personnes ayant le poids le plus \u00e9lev\u00e9, la warfarine \u00e9tait toujours utilis\u00e9e.\nMots-cl\u00e9s : fibrillation auriculaire, ob\u00e9sit\u00e9, anticoagulants oraux, anticoagulation, interventions du pharmacien, pharmacien<\/jats:p>","DOI":"10.4212\/cjhp.3425","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T17:31:33Z","timestamp":1710351093000},"source":"Crossref","is-referenced-by-count":0,"title":["Characterization of Antithrombotic Regimens for Patients with Nonvalvular Atrial Fibrillation and Obesity Discharged from Cardiology Wards"],"prefix":"10.4212","volume":"77","author":[{"given":"Stephanie","family":"O'Byrne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Tangedal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Semchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2732","published-online":{"date-parts":[[2024,3,13]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3425\/5229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3425\/5236","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3425\/5229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T17:31:33Z","timestamp":1710351093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,10]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3425","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"type":"electronic","value":"1920-2903"},{"type":"print","value":"0008-4123"}],"subject":[],"published":{"date-parts":[[2024,3,13]]}}}